CoChat

Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies

Open access
Abdel-Wahab, Omar, Klimek, Virginia M., Gaskell, Alisa A., Viale, Agnes, Cheng, Donavan, Kim, Eunhee, Rampal, Raajit, Bluth, Mark, Harding, James J., Callahan, Margaret K., Merghoub, Taha, Berger, Michael F., Solit, David B., Rosen, Neal, Levine, Ross L., Chapman, Paul B. · 2014 · Cancer Discovery
Cited by 80

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Vemurafenib, a RAF inhibitor, extends survival in patients with BRAFV600-mutant melanoma but activates extracellular signal–regulated kinase (ERK) signaling in RAS-mutant cells. In a patient with a BRAFV600K-mutant melanoma responding to vemurafenib, we observed accelerated progression of a previously unrecognized NRAS-mutant leukemia. We hypothesized that combining vemurafenib with a MAP–ERK kinase (MEK) inhibitor would inhibit ERK activation in the melanoma and prevent ERK activation by vemurafenib in the leukemia, and thus suppress both malignancies. We demonstrate that intermittent administration of vemurafenib led to a near-complete remission of the melanoma, and the addition of the MEK inhibitor cobimetinib (GDC-0973) caused suppression of vemurafenib-induced leukemic proliferation and ERK activation. Antimelanoma and antileukemia responses have been maintained for nearly 20 months, as documented by serial measurements of tumor-derived DNA in plasma in addition to conventional radiographic and clinical assessments of response. These data support testing of intermittent ERK pathway inhibition in the therapy for both RAS-mutant leukemia and BRAF-mutant melanoma. Significance: We show that in a patient with simultaneous RAS-mutant leukemia and BRAF-mutant melanoma, intermittent RAF inhibitor therapy induced a near-complete melanoma response, and addition of a MEK inhibitor prevented RAF inhibitor-induced activation of the RAS-mutant leukemia. Intermittent therapy may permit greater pathway inhibition with less toxicity, avoid chronic relief of pathway feedback, and have enhanced effectiveness compared with chronic administration. Cancer Discov; 4(5); 538–45. ©2014 AACR. See related commentary by Davies, p. 510 This article is highlighted in the In This Issue feature, p. 495

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-13-1038

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 80

Metadata

Authors
Abdel-Wahab, O., Klimek, V. M., Gaskell, A. A., Viale, A., Cheng, D., Kim, E., Rampal, R., Bluth, M., Harding, J. J., Callahan, M. K., Merghoub, T., Berger, M. F., Solit, D. B., Rosen, N., Levine, R. L., & Chapman, P. B.
Venue
Cancer Discovery
Published
2014-05-01
Volume
4
Issue
5
Pages
538-545
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2105317859
Cited by
80
References
5
FWCI
5.23
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies. https://app.cochat.ai/papers/10.1158/2159-8290.cd-13-1038
The paper
Abdel-Wahab, O., Klimek, V. M., Gaskell, A. A., Viale, A., Cheng, D., Kim, E., Rampal, R., Bluth, M., Harding, J. J., Callahan, M. K., Merghoub, T., Berger, M. F., Solit, D. B., Rosen, N., Levine, R. L., & Chapman, P. B. (2014). Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-13-1038

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.